Global Poly Adp Ribose Polymerase Parp Inhibitors Market Companies

Pharmaceutical
Oct 2024
Global
350 Pages
No of Tables: 220
No of Figures: 60

Buy Now

Request for Sample

Nucleus

Companies Covered

Highest Market Share

Dominant Companies

Other Companies

Global Poly Adp Ribose Polymerase Parp Inhibitors Market Share Analysis

The data presented is for visualization purposes only and may not reflect actual results.

Nucleus : Company Analysis Platform

Request for Demo >

Frequently Asked Questions

Who are major players in Poly (ADP-Ribose) Polymerase (PARP) inhibitors market?

Companies such as AstraZeneca (U.K.), Merck & Co., Inc., (U.S.), GSK plc. (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), are major players in Poly (ADP-Ribose) Polymerase (PARP) inhibitors market.

What are the recent product launches by major companies in the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market?

In February 2025, A comprehensive review published reaffirmed Olaparib's leadership among PARP inhibitors in boosting overall survival for platinum-sensitive recurrent ovarian cancer, indicating its potential as a preferred option for patients. In May 2024, The Re-VOLVE Phase II clinical trial (NCT05065021), presented in May 2025, investigates a chemo-free approach for women with ovarian cancer progressing post-PARP inhibitor treatment, adapting therapy to real-time assessment of evolving genomic resistance. This highlights the ongoing efforts to personalize PARP inhibitor treatment and address resistance

Which countries data is covered in the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market?

The countries covered in the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.